CClinicalTrials.gg
Sign In
CompletedNCT00653965STARSHIPUpdated Mar 16, 2009

Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)

A Phase 3 interventional study of Rosuvastatin and Atorvastatin in Hypercholesterolemia and Dyslipidaemia, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in Hispanic subjects with hypercholesterolemia

02

Conditions studied

  • Hypercholesterolemia
  • Dyslipidaemia

Keywords

  • Cholesterol
  • low density lipoproteins
  • dyslipidaemia
  • Rosuvastatin
  • Crestor
  • Atorvastatin
  • Lipitor
  • Hispanic
03

In context

Hypercholesterolemia

1,238 studies on the registry are indexed under Hypercholesterolemia; 109 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 99 across 991 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Fasting low density lipoprotein \& triglyceride levels as defined by the protocol.
  • Self described Hispanic race
  • Subjects with coronary heart disease or at high risk of coronary heart disease.

Exclusion criteria

Exclusion Criteria:

  • The use of lipid lowering drugs or dietary supplements after Visit 1.
  • Active arterial disease eg Unstable angina, or recent arterial surgery
  • Blood lipid levels above the limits defined in the protocol.
  • Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,000 participants (estimated)

Study arms

  • Experimental
    1

    Rosuvastatin

    Drug: Rosuvastatin

  • Active comparator
    2

    Atorvastatin

    Drug: Atorvastatin

Interventions

  • DrugRosuvastatin

    Also known as: Crestor

  • DrugAtorvastatin

    Also known as: Lipitor

06

What researchers measure

Primary outcomes

  1. Low density lipoproteins cholesterol levels

    Time frame: 6 weeks

Secondary outcomes

  1. Other blood lipid level changes

    Time frame: 6 weeks

  2. Safety: adverse events & abnormal laboratory markers

    Time frame: 6 weeks

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00653965
Lead sponsor
AstraZeneca
First posted
Apr 7, 2008
Start date
May 2003
Completion
Feb 2005
Last update
Mar 16, 2009

Study contacts

Steve Haffner, MD
principal investigator · San Antonio, USA
Russell Esterline
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hypercholesterolemia→

Other studies from this sponsor

AstraZeneca

Start the discussion